A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors

We report the case of a 53-year-old woman affected by metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who received ALK tyrosine kinase inhibitors, from January 2017. The patient had a complete response of choroidal metastasis after therapy with ALK tyrosine kinase inhibitors. She recovered a complete visus and actually she still continue therapy with alectinib. The patient had a complete recovery of visus in addiction to a long response on treatment.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research